We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Looks like the seller is now out, after those 2 £58k sells
Must be news due soon, they're driving it down again....this had a higher valuation before we even got the extra funding...game of snakes and ladders..
I added a few last week, let's hope for MALT-1 programme news next !
The announcement of a partnership re the MALT-1 programme will be the next big mover here and that could come at any time.
1 June 2023 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, provides an update on its MALT-1 inhibitor programme for cancer. C4XD has successfully completed a preclincial study demonstrating its MALT-1 lead compounds are free of UGT1A11 liability shown by competitor chemistries. The C4XD MALT-1 inhibitor programme is continuing to identify a shortlist of pre-clinical candidates for further development and a partnering programme has been initiated.
We are told to " buy on the rumour and sell on the fact", so hopefully there is no definitive news this week.
Sanofi milestone payment must be very close now, possibly this week.
Could see something big here
two titans are in bed with C4XD!!
https://twitter.com/EquityTrader888/status/1750509151728316523?t=W3oHVgZCV2DuARyDGNf6SA&s=19
Found something significant on online about Sanofi.....
see if I can post it here later today
EarlofAim - Biggest liar and pumper on LSE.
C4X doesn't need pumping. Large proportion of mcap is backed by cash and multiple $400m milestone deals with majors, several more in the pipeline.
Https://www.fiercebiotech.com/biotech/sanofi-inks-17b-inhibrx-buyout-snagging-rare-disease-drug-spinning-out-cancer-programs
2.2Billion dollar deal with Sanofi
huge potential here as C4XD already have Sanofi milestones paid,could takeover be next
Hello Petroinvestor
my lucky charm
thanks for coming here,
HE1 done well, like I posted helium would be found, but didn't say the grade.
This is being pumped by the usual pump-and-dump crews. Stay away, or you will be left holding the bag!
EarlofAim, how many stocks you and Ria20 P&D and the newbies left holding the baby?
Beware of people who give you stock tips with random price targets. They are likely pump-and-dumpers who are trying to offload their shares at a higher price. Newbies often fall for this scam and end up losing money.
EarlofAim Twitter accounts:
Equity-Trader - https://twitter.com/EquityTrader888
Investology - https://twitter.com/Profitprofit1
Check for yourself how many pump-and-dump posts he posts every day and back it up with his LSE posts to scam investors.
C4XD got £3m from Sanofi and back in July 2022
time to get big milestone.....
Congratulations to the #C4XD team getting their first £3m milestone payment from #sanofi. Life Science, especially the Biotech development side can be a tough business, but validation like this makes the tough times worth it.
Https://www.fiercebiotech.com/biotech/sanofi-inks-17b-inhibrx-buyout-snagging-rare-disease-drug-spinning-out-cancer-programs
2.2Billion dollar deal with Sanofi
huge potential here as C4XD already have Sanofi milestones paid,could takeover be next?
$2.2Billion dollar deal with Sanofi
huge potential here as C4XD already have Sanofi milestones paid,could takeover be next?
https://www.pmlive.com/pharma_news/sanofi_expands_rare_disease_pipeline_with_$2.2bn_inhibrx_acquisition_1507199?SQ_DESIGN_NAME=2&
Congratulations to the #C4XD team getting their first £3m milestone payment from #sanofi. Life Science, especially the Biotech development side can be a tough business, but validation like this makes the tough times worth it.
Starting to rise again. Expectation of sanofi milestone payment very soon now
Yes a good article DD77. Would be interesting to know the future timelines for receipt of the subsequent milestone payments from Sanofi and AZ.
I Googled Sanofi's pipeline of drugs under research and development but could not locate the one that Sanofi made the payment to C4X for. However, they could be calling it by some other biopharma description. Not being a chemist, all double Dutch to me!
Good write up and interview. Worth a read
https://www.proactiveinvestors.co.uk/companies/news/1038104/c4xd-a-biotechnology-pioneer-in-immuno-inflammation-1038104.html
First time poster, on verge of retiring and going to spend more time of my hobby, in investing in early stage companies, with growth prospects.
The correction in the share price today, I do not believe is down to I institutional investors taking profits, as one poster indicated. I cannot see II's selling off such small amounts of stock. More like private investors seeing the share price slightly falling, worrying and joing the herd, making the price drop more than it might have been. In other words, taking the short term speculative view.
Taking the longer view, when the next interim accounts and full YE results come out, readers should hopefully see:
- total income in previous financial year: £1.7m
-without any further income from now, income on a comparable basis, will include Invidior £15.95m and
Astra Zeneca $11m.
That comparison in itself will attract attention, although sales are not profit.
Even if cost of sales and overheads are similar to previous year, this would indicate positive EBIT being the result.
There will be minimal, if nil debt. Another tremendous positive in the current interest rate environment.
Even if company continues to burn cash with further R and D on new innovative solutions for medical conditions, at the same level as last year, I believe should be more than enough cash in bank for circa eighteen months to two years, even without any additional interim milestone payments from Sanofi or AZ, that may be received.
As previous contributors have already mentioned, there could be interest from larger biopharm entities in this little company.
In summary, one in my view to have in your portfolio for the long term (but not for widows/widowers or orphans) , as long as you can ride out the roller coaster ride!
Absolutely spot on Newuncle. Today has been an opportunity...again
No, it's PIs being scared into selling their shares to keep their profits before they get taken away by MMs looking for shares for the next leg up.
Now trading at pretty much cash again.